Cyclosporine markedly raises the plasma concentrations of repaglinide

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 4, 2005, Pages 388-399

  Kajosaari, Lauri I ^b   Niemi, Mikko ^b   Neuvonen, Mikko ^b   Laitila, Jouko ^b   Neuvonen, Pertti J ^b   Backman, Janne T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; GLYCOPROTEIN P; ORGANIC ANION TRANSPORTER; PLACEBO; REPAGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE INTAKE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME ACTIVITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; IC 50; LIVER MICROSOME; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; CARBAMATES; CROSS-OVER STUDIES; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROSOMES, LIVER; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 25844438751     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.07.005     Document Type: Article

References (42)

1. J. Gromada, S. Dissing, H. Kofod, J. Frøkjaer-Jensen Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells Diabetologia 38 1995 1025 1032
2. V. Hatorp Clinical pharmacokinetics and pharmacodynamics of repaglinide Clin Pharmacokinet 41 2002 471 483
3. V. Hatorp, S. Oliver, C.A. Su Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers Int J Clin Pharmacol Ther 36 1998 636 641
4. L.I. Kajosaari, J. Laitila, P.J. Neuvonen, J.T. Backman Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro effect of fibrates and rifampicin Basic Clin Pharmacol Toxicol 97 2005 249 256
5. T.B. Bidstrup, I. Bjørnsdottir, U.G. Sidelmann, M.S. Thomsen, K.T. Hansen CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide Br J Clin Pharmacol 56 2003 305 314
6. P.N. van Heiningen, V. Hatorp, K. Kramer Nielsen, K.T. Hansen, J.J. van Lier, N.C. De Merbel Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing Eur J Clin Pharmacol 55 1999 521 525
7. M. Niemi, J.T. Backman, L.I. Kajosaari, J.B. Leathart, M. Neuvonen, A.K. Daly Polymorphic organic anion transporting polypeptide 1B1 (OATP1B1) is a major determinant of repaglinide pharmacokinetics Clin Pharmacol Ther 77 2005 468 478
8. V. Hatorp, K.T. Hansen, M.S. Thomsen Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide J Clin Pharmacol 43 2003 649 660
9. M. Niemi, J.T. Backman, M. Neuvonen, P.J. Neuvonen Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide potentially hazardous interaction between gemfibrozil and repaglinide Diabetologia 46 2003 347 351
10. M. Niemi, L.I. Kajosaari, M. Neuvonen, J.T. Backman, P.J. Neuvonen The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects Br J Clin Pharmacol 57 2004 441 447
11. M. Niemi, P.J. Neuvonen, K.T. Kivistö The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide Clin Pharmacol Ther 70 2001 58 65
12. J.T. Backman, C. Kyrklund, K.T. Kivistö, J.S. Wang, P.J. Neuvonen Plasma concentrations of active simvastatin acid are increased by gemfibrozil Clin Pharmacol Ther 68 2000 122 129
13. J.S. Wang, M. Neuvonen, X. Wen, J.T. Backman, P.J. Neuvonen Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes Drug Metab Dispos 30 2002 1352 1356
14. Y. Shitara, M. Hirano, H. Sato, Y. Sugiyama Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil J Pharmacol Exp Ther 311 2004 228 236
15. C.J. Dunn, A.J. Wagstaff, C.M. Perry, G.L. Plosker, K.L. Goa Cyclosporin an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation Drugs 61 2001 1957 2016
16. A. Åsberg Interactions between cyclosporin and lipid-lowering drugs implications for organ transplant recipients Drugs 63 2003 367 378
17. Y. Shitara, T. Itoh, H. Sato, A.P. Li, Y. Sugiyama Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A J Pharmacol Exp Ther 304 2003 610 616
18. M.F. Hebert Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery Adv Drug Deliv Rev 27 1997 201 214
19. V. Stapf, T. Thalhammer, R. Huber-Huber, F. Felberbauer, L. Gajdzik, J. Graf Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver Anticancer Res 14 1994 581 585
20. L. Renders, D. Czock, H. Schocklmann, U. Kunzendorf Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature Int J Clin Pharmacol Ther 41 2003 499 503
21. S.G. Simonson, A. Raza, P.D. Martin, P.D. Mitchell, J.A. Jarcho, C.D. Brown Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine Clin Pharmacol Ther 76 2004 167 177
22. J.W. Park, R. Siekmeier, M. Merz, B. Krell, S. Harder, W. Marz Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A Int J Clin Pharmacol Ther 40 2002 439 450
23. M. Hedman, P.J. Neuvonen, M. Neuvonen, C. Holmberg, M. Antikainen Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression Clin Pharmacol Ther 75 2004 101 109
24. M.B. Regazzi, I. Iacona, C. Campana, A. Gavazzi, M. Vigano, G. Perani Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A Transplant Proc 26 1994 2644 2645
25. M. Niemi, J.B. Leathart, M. Neuvonen, J.T. Backman, A.K. Daly, P.J. Neuvonen Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide Clin Pharmacol Ther 74 2003 380 387
26. J.T. Backman, C. Kyrklund, M. Neuvonen, P.J. Neuvonen Gemfibrozil greatly increases plasma concentrations of cerivastatin Clin Pharmacol Ther 72 2002 685 691
27. C.E. Ong, S. Coulter, D.J. Birkett, C.R. Bhasker, J.O. Miners The xenobiotic inhibitor profile of cytochrome P4502C8 Br J Clin Pharmacol 50 2000 573 580
28. K.T. Olkkola, J.T. Backman, P.J. Neuvonen Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 55 1994 481 485
29. J.C. Gorski, D.R. Jones, B.D. Haehner-Daniels, M.A. Hamman, E.M. O'Mara Jr, S.D. Hall The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin Clin Pharmacol Ther 64 1998 133 143
30. G. Li, G. Treiber, J. Meinshausen, J. Wolf, J. Werringloer, U. Klotz Is cyclosporin A an inhibitor of drug metabolism? Br J Clin Pharmacol 30 1990 71 77
31. I. Tamai, A.R. Safa Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells J Biol Chem 265 1990 16509 16513
32. Z.S. Chen, T. Kawabe, M. Ono, S. Aoki, T. Sumizawa, T. Furukawa Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter Mol Pharmacol 56 1999 1219 1228
33. M. Arnadottir, L.O. Eriksson, H. Thysell, J.D. Karkas Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin Nephron 65 1993 410 413
34. R. Goldberg, D. Roth Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine Transplantation 62 1996 1559 1564
35. L. Gullestad, K.P. Nordal, K.J. Berg, H. Cheng, M.S. Schwartz, S. Simonsen Interaction between lovastatin and cyclosporine A after heart and kidney transplantation Transplant Proc 31 1999 2163 2165
36. C. Kyrklund, J.T. Backman, M. Neuvonen, P.J. Neuvonen Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance Clin Pharmacol Ther 73 2003 538 544
37. C. Kyrklund, J.T. Backman, K.T. Kivistö, M. Neuvonen, J. Laitila, P.J. Neuvonen Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin Pharmacol Ther 69 2001 340 345
38. D.W. Schneck, B.K. Birmingham, J.A. Zalikowski, P.D. Mitchell, Y. Wang, P.D. Martin The effect of gemfibrozil on the pharmacokinetics of rosuvastatin Clin Pharmacol Ther 75 2004 455 463
39. B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, W.P. Yang A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J Biol Chem 274 1999 37161 37168
40. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes J Pharmacol Exp Ther 297 2001 861 867
41. J. Martin, H. Krum Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class are they clinically relevant? Drug Saf 26 2003 13 21
42. K.T. Kivistö, J. Zukunft, U. Hofmann, M. Niemi, S. Rekersbrink, S. Schneider Characterisation of cerivastatin as a P-glycoprotein substrate studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice Naunyn Schmiedebergs Arch Pharmacol 370 2004 124 130